Clinical effectiveness and cost savings in diabetes care, supported by pharmacist counselling

详细信息    查看全文

• 作者：Magaly Rodriguez de BittnerAuthor Vitae ; Viktor V. ChirikovAuthor Vitae ; Ian M. BreunigAuthor Vitae ; Roxanne W. ZaghabAuthor Vitae ; Fadia Tohme Shaya ; ^{fshaya@rx.umaryland.edu}Author Vitae
• 刊名：Journal of the American Pharmacists Association
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：57
• 期：1
• 页码：102-108.e4
• 全文大小：479 K
• 卷排序：57

文摘

To determine the effectiveness and cost savings of a real-world, continuous, pharmacist-delivered service with an employed patient population with diabetes over a 5-year period.SettingThe Patients, Pharmacists Partnerships (P3 Program) was offered as an “opt-in” benefit to employees of 6 public and private self-insured employers in Maryland and Virginia. Care was provided in ZIP code–matched locations and at 2 employers' worksites.Practice descriptionSix hundred two enrolled patients with type 1 and 2 diabetes were studied between July 2006 and May 2012 with an average follow-up of 2.5 years per patient. Of these patients, 162 had health plan cost and utilization data. A network of 50 trained pharmacists provided chronic disease management to patients with diabetes using a common process of care. Communications were provided to patients and physicians.Practice innovationEmployers provided incentives for patients who opted in, including waived medication copayments and free diabetes self-monitoring supplies. The service was provided at no cost to the patient. A Web-based, electronic medical record that complied with the Health Insurance Portability and Accountability Act helped to standardize care. Quality assurance was conducted to ensure the standard of care.EvaluationGlycosylated hemoglobin (A1c), blood pressure, and total health care costs (before and after enrollment).ResultsStatistically significant improvements were shown by mean decreases in A1c (−0.41%, P <0.001), low-density lipoprotein levels (−4.7 mg/dL, P = 0.003), systolic blood pressure (−2.3 mm Hg, P = 0.001), and diastolic blood pressure (−2.4 mm Hg, P <0.001). Total annual health care costs to employers declined by $1031 per beneficiary after the cost of the program was deducted. This 66-month real-world study confirms earlier findings. Employers netted savings through improved clinical outcomes and reduced emergency and hospital utilization when comparing costs 12 months before and after enrollment.ConclusionThe P3 program had positive clinical outcomes and economic outcomes. Pharmacist-provided comprehensive medication therapy management services should be included as a required element of insurance offered by employers and health insurance exchanges.